Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.65  0.04  1.53%   
About 52% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at zacks.com         
Lisatas Lead Cancer Drug Gets ECs Orphan Tag, Stock Up
zacks News
over a year ago at finance.yahoo.com         
Lisatas Lead Cancer Drug Gets ECs Orphan Tag, Stock Up
Yahoo News
over a year ago at news.google.com         
Lisata Therapeutics Announces European Medicines Agency Has ... - Marketscreener.com
Google News at Macroaxis
over a year ago at marketwatch.com         
Lisata Therapeutics Shares Rise 11 percent After Cancer Drug LSTA1 Granted Orphan Drug Status in EU
marketwatch News
over a year ago at finance.yahoo.com         
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation fo...
Yahoo News
over a year ago at kalkinemedia.com         
Dovitinib, a potential new treatment for osteosarcoma, receives Orphan Drug Designation from the U.S...
news
over a year ago at news.google.com         
CISOs push for baseline AI business rules - SC Media
Google News at Macroaxis
over a year ago at news.google.com         
Lisata Therapeutics Announces Participation in Upcoming ... - Marketscreener.com
Google News at Macroaxis
over a year ago at globenewswire.com         
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
Macroaxis News: globenewswire.com
over a year ago at news.google.com         
Lisata Therapeutics Announces Participation in InfoSec World 2023 ... - Marketscreener.com
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Lisata Therapeutics Announces Participation in InfoSec World 2023
Yahoo News
over a year ago at news.google.com         
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Tar...
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Tar...
Yahoo News
over a year ago at thelincolnianonline.com         
Lisata Therapeutics Shares Up 1.4
news
over a year ago at news.google.com         
Phase 2 ASCEND Trial Will Continue Investigating LSTA1 in mPDAC - Targeted Oncology
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Forte Biosciences, Inc. Announces Oversubscribed 53 Million Private Placement From Leading ...
11/20/2024
2
Castle Biosciences director Daniel Bradbury sells 243,692 in stock
12/05/2024
3
Castle Biosciences CEO Derek Maetzold sells 160,741 in shares
12/09/2024
4
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
12/10/2024
5
Lisata Therapeutics Given Buy Rating at HC Wainwright
12/11/2024
6
Parse Biosciences bringt Evercode Mouse BCR auf den Markt, um die Entwicklung und Herstellung von Antikrpern fr Anwendungen in der Arzneimittelforschung zu unte...
12/12/2024
7
Solid Biosciences SWOT analysis gene therapy stocks potential in DMD treatment
12/13/2024
8
Why Forte Biosciences Stock Is Trading Lower
12/16/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes